Antibodies

Proteins that are part of your immune system and help protect your body. Antibodies attack different things that are foreign to your body.2

ABR

Annual bleed rate, the number of bleeds in one year.

Blood Clot

A thickened mass in the blood formed by platelets.25

Bypassing Agents

Treatments given to patients with inhibitors to help their blood clot by getting around the normal way that clots form.9

Clotting Cascade

A series of steps that occur in the formation of a clot involving the clotting proteins and other substances.26

Clotting Factor

Substances in your blood that help it clot. The different factors are named with Roman numerals and include factors I, II, III, IV, V, VII, VIII, IX, X, XI, XII, and XIII. An "a" after the Roman numeral means that it's an activated type of that factor (factor VIIIa, IXa, etc).26

Episodes

Events or incidents.

Factor

See "Clotting Factor."

Hemophilia

A condition that stops your blood from clotting normally due to partial or complete lack of one of the clotting factors, such as FVIII or FIX.26

Hemophilia A

The type of hemophilia caused by partial or complete lack of factor VIII.26

Hemophilia B

The type of hemophilia caused by partial or complete lack of factor IX.26

Infusion

The administration of clotting factor concentrates.26

Inhibitors

Agents that block a biological or chemical process. In hemophilia, they are antibodies that attack and inactivate your factor replacement treatment and stop them from helping your blood to clot.26

Plasma

The protein-rich portion of the blood that carries the red blood cells, white blood cells, and platelets.26

Prophylaxis

Routine infusion to help prevent bleeds.26

On Demand

As-needed infusion to treat bleeds when they happen.20

Sign up
See LessMore

What is FEIBA?

FEIBA is an Anti-Inhibitor Coagulant Complex approved for use in hemophilia A and B patients with inhibitors for:

  • Control and prevention of bleeding episodes

Detailed Important Risk Information

What is FEIBA?

FEIBA is an Anti-Inhibitor Coagulant Complex approved for use in hemophilia A and B patients with inhibitors for:

  • Control and prevention of bleeding episodes
  • Use around the time of surgery
  • Routine prophylaxis to prevent or reduce the frequency of bleeding episodes

Detailed Important Risk Information

  • Blood clots that block blood vessels and their effects have been reported during post-marketing surveillance following infusion of FEIBA, particularly following administration of high doses (above 200 units per kg per day) and/or in patients at risk for forming blood clots.
  • If you experience any of these side effects, call your doctor right away.